Redefining Readiness: Are We Prepared for the Bispecific Era in Multiple Myeloma?

An expert discusses the integration of bispecific antibodies into relapsed/refractory multiple myeloma care pathways, highlighting the importance of stakeholder alignment, care coordination, and patient onboarding, while emphasizing strategies for education and shared decision-making to support informed treatment choices.